James George Chopas Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

James George Chopas is VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 48,138 shares of APLS, which is worth approximately $1.4 Million. The most recent transaction as insider was on Jan 22, 2025, when has been sold 1,096 shares (Common Stock) at a price of $30.43 per share, resulting in proceeds of $33,351. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 48.1K

26.21% 3M change

23.22% 12M change

Total Value Held $1.4 Million

James George Chopas Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 22 2025	SELL Open market or private sale	$33,351 $30.43 p/Share	1,096 Reduced 2.23%	48,138 Common Stock
Jan 21 2025	BUY Grant, award, or other acquisition	-	12,591 Added 20.37%	49,234 Common Stock
Jan 17 2025	SELL Open market or private sale	$21,421 $29.96 p/Share	715 Reduced 1.91%	36,643 Common Stock
Jan 13 2025	SELL Open market or private sale	$22,472 $28.7 p/Share	783 Reduced 2.05%	37,358 Common Stock
Sep 16 2024	SELL Open market or private sale	$6,952 $36.21 p/Share	192 Reduced 0.5%	38,141 Common Stock
Sep 03 2024	SELL Open market or private sale	$21,719 $39.49 p/Share	550 Reduced 1.41%	38,333 Common Stock
Mar 15 2024	SELL Open market or private sale	$10,388 $56.46 p/Share	184 Reduced 0.47%	38,883 Common Stock
Jan 22 2024	SELL Open market or private sale	$68,965 $65.0 p/Share	1,061 Reduced 2.64%	39,067 Common Stock
Jan 16 2024	SELL Open market or private sale	$57,723 $66.81 p/Share	864 Reduced 2.11%	40,128 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	8,312 Added 16.86%	40,992 Common Stock
Oct 23 2023	SELL Open market or private sale	$6,077 $46.04 p/Share	132 Reduced 0.4%	32,680 Common Stock
Sep 14 2023	BUY Grant, award, or other acquisition	-	2,500 Added 7.08%	32,812 Common Stock
Aug 31 2023	SELL Open market or private sale	$22,717 $41.23 p/Share	551 Reduced 1.79%	30,312 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$19,539 $58.5 p/Share	334 Reduced 1.07%	30,863 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	4,044 Added 11.48%	31,197 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$47,833 $52.05 p/Share	919 Reduced 3.27%	27,153 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	9,621 Added 25.52%	28,072 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	9,621 Added 25.52%	28,072 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	9,621 Added 25.52%	28,072 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	9,621 Added 25.52%	28,072 Common Stock
Oct 20 2022	SELL Payment of exercise price or tax liability	$7,540 $58.0 p/Share	130 Reduced 0.7%	18,451 Common Stock
Aug 30 2022	SELL Payment of exercise price or tax liability	$32,833 $58.84 p/Share	558 Reduced 2.92%	18,581 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	6,974 Added 31.09%	15,456 Common Stock
Oct 20 2021	BUY Grant, award, or other acquisition	-	882 Added 9.42%	8,482 Common Stock
Aug 30 2021	BUY Grant, award, or other acquisition	-	7,600 Added 50.0%	7,600 Common Stock

Also insider at

RDUS

Radius Health, Inc. Healthcare

Principal Finance Accounting

JGC